Background {#Sec1}
==========

Low-grade gliomas include astrocytoma, oligodendrogliomaand oligoastrocytoma of WHO gradeI-II \[[@CR1]\]. The incidence of low-grade gliomas is significantly lower than that of high-grade glioblastomas of all primary intracranial tumors \[[@CR2]\]. The epidemiological features, clinical manifestations, proliferation rates, mitotic counts, as well as angiogenesis and genetic features of low-grade gliomas are different from those of high-grade gliomas \[[@CR3]\]. Low-grade gliomas have a better prognosis than high-grade gliomas. The established risk factors influencing the prognosis of high-grade gliomas include IDH mutation, age, KPS score, and the extent of resection \[[@CR4]\]. However, the prognostic factors of low-grade gliomas are not fully elucidated yet. So far, only IDH mutation, KPS score, age and the pathological type are recognized as factors related to the prognosis of low-grade gliomas \[[@CR5]\], the effect on prognosis of extent of resection of low-grade gliomas has not been systematically evaluated.

Many neurosurgeons recommend performing the greatest extent of resection safely possible for both high-grade and low-grade gliomas. In the past, the available surgical techniques might make it difficult to access gliomas in deep locations or in the brain functional areas \[[@CR6]\]. However, with the use of neuronavigator and intraoperative MRI, many difficulties in accessing the tumors in challenging locations been solved \[[@CR7]\]. High-grade gliomas have a higher incidence and their median survival ranges from 1 to 2 years \[[@CR4]\]. A large number of researches have tried to elucidate the association between the extent of resection and the prognosis of high-grade gliomas. There are explicit first-level evidences indicating that a gross total resection (GTR) can significantly increase the overall survival (OS) and progression-free survival (PFS) of patients as compared with a subtotal resection (STR) or biopsy(BX) \[[@CR8]\]. In contrast, low-grade gliomas have a lower incidence and a better prognosis. The medial survival of patients with low-grade gliomas is 5 to 10 years \[[@CR3]\]. However, there are much fewer cases of low-grade gliomas and relevant clinical trials are hindered by long trial durations and ethical principles. At present, few researches have been focused on the relationship between the extent of resection and the prognosis of low-grade gliomas. Therefore, no randomized trials or first-level evidence have demonstrated explicitly the relationship between the extent of resection and prognosis.

It remains controversial whether a greater extent of resection can increase the OS and PFS of patients with low-grade gliomas. We performed a meta-analysis to prove the relationship between the extent of resection and the prognosis of patients with low-grade gliomas, then provide a basis for the development of evidence-based medicines in low-grade gliomas.

Methods {#Sec2}
=======

Search strategy and study selection {#Sec3}
-----------------------------------

Using the PICO strategy, PubMed and EMBASE were searched for publications up to March 2017. The keywords chosen for the search included low-grade glioma (WHO gradeI-II), extent of resection, resection, biopsy and survival. The scope of search was expanded by combining the keywords with non-keywords according to the restriction of the English-language. Auxiliary search techniques such as keywords expansion were used to increase the recall rate. Detailed search strategies for both databases are shown in Additional file [1](#MOESM1){ref-type="media"}: Appendix 1.

Search was performed according to the above strategy to obtain the titles of relevant articles. Subsequently, the search strategy was adjusted based on the number of articles obtained after the preliminary search. Articles obtained in this manner were further screened. For systemic reviews related to this topic, their bibliographies were searched to identify potential articles.

All included articles were reviewed by two independent reviewers (Xia L and Fang CY). All disagreements were settled through discussion. If the disagreements could not be settled, a third party was invited to make a final decision. The eligible criteria were as follows: (1) Patients with low-grade gliomas diagnosed by pathology; (2) Adult patients with lesions in the supratentorial region; (3) Trials discussing the relationship between the extent of resection (GTR, STR or biopsy) and prognosis (OS or PFS); (4) 5-year or 1-year OS data were available or could be calculated from other results such as survival plots; (5) If the included cases overlapped, the trial with a greater number of cases would be included. Exclusion criteria were as follows: (1) Patients were pathologically diagnosed as high-grade gliomas in most of the cases included in the article; (2) Patients with pediatric gliomas or subtentorial gliomas; (3) The extent of resection was expressed as percentages rather than GTR, STR and biopsy; (4) 5-year or 10-year survival data were not available.

Data extraction {#Sec4}
---------------

Low-grade gliomas are associated with a better prognosis and only a few studies have been focused on the 1-year or 2-year survival of patients with low-grade gliomas. The literature search also yielded a limited number of studies covering this topic. Therefore, the topic in the search was changed to the association between the extent of resection and 5-year and 10-year OS of patients with low-grade gliomas. Data extraction was performed by two independent reviewers, and the data included the name of the first author, publication time, country, sample size, patients' age, tumor type, the extent of resection, 5-year or 10-year OS and the duration of follow-up. The extent of resection was divided into three categories, i.e., GTR, STR and BX. STR included both subtotal resection and partial resection. If the survival rate was not mentioned when endpoints were reached, the survival rate was calculated from the Kaplan-Meier curve. Already mentioned that disagreements were settled with discussion.

Quality assessment of primary studies {#Sec5}
-------------------------------------

The quality of each article was assessed using American Academy of Neurology level of evidence criteria by a research team with four members. All included articles were scored independently by four members and then the sum score was obtained. Any disagreement was settled through discussion until a consensus was reached. The included articles were classified into level I-IV. Among them, Level I indicated the best quality while level IV indicated the lowest credibility.

After data sorting and meta-analysis, the credibility of evidence was assessed using the GRADE system. There were four levels of credibility, i.e., high, moderate, low and very low. A high quality was assigned if the outcome assessment could be altered by further studies; a moderate quality was assigned if the credibility of the outcome assessment and the outcome assessment itself might be altered by further studies; a moderate quality was assigned if the credibility of the outcome assessment and the outcome assessment itself might be altered by further studies; a very low quality was assigned if any outcome assessment was uncertain.

Statistical analysis {#Sec6}
--------------------

Revman5.3 software provided by Cochrane collaboration was employed. Depending on the forest plot and results from the tests of heterogeneity, a fixed effects model or a random effects model was chosen. The relationships among categorical variables were analyzed using an odds ratio (OR) and a95% confidence interval (CI). Significance was established using CIs at a level of 95% or *P* \< 0.05.Logarithmicdata were processed by weighting on the basis of sample size. That is, the greater the sample size, the greater the weight was assigned. Funnel plot was used to detect the publication bias.

Results {#Sec7}
=======

Literature search {#Sec8}
-----------------

According to the search strategy, a total of 1230 English articles (Fig. [1](#Fig1){ref-type="fig"}) were eligible. After reviewing the titles, abstracts and full texts, 1210 articles were excluded. Finally, 20 articles involving 2128 cases were included for the meta-analysis (one was a randomized and controlled trial (RCT) and 19 were retrospective studies).Fig. 1Flowchart of study selection

Article quality assessment {#Sec9}
--------------------------

None of the included articles was a class Level I study. There were 4 \[[@CR9]--[@CR12]\] class Level II studies, 13 \[[@CR13]--[@CR25]\] class Level III studies and 3 \[[@CR26]--[@CR28]\] class Level IV studies (Table [1](#Tab1){ref-type="table"}). Only 1 study involved a prospective RCT.Table 1Included study characteristicsStudyPublication TimeYears of Patient AccrualCountryStudy TypeNo. of PatientsNo. of AnalysisMedian Follow UpHistologyAdjuvant TherapiesEOR assessmentLevel of EvidenceWINGE(9)19891982--1987Londonretrospective study285187NSGlioblastoma multiforme 188\
Astrocytoma 76\
Mixed 11\
Oligodendroglioma 10\
Astrocytoma or mixed A \> O 32RTNSIIShaw(10)20021986--1994Mayoretrospective study2032036.4 yearsOligodendroglioma or mixed O \> A 69RTNSIIHARMON J(11)19931980--1985USA (Michigan)prospective randomized trial60604.5 yearsLow-grade GliomaRT + ChNSIIEdward G(12)19941960--1982Mayoretrospective study717115 yearsOligoastrocytomaRToperative reportIIR. Laws(13)19841915--1975Mayoretrospective study85146115 year\
MAXAstrocytomaRTmicroscopicallyIIILINDEGAARD(14)19871953--1977Norwayretrospective study585823 years\
MAXOligodendrogliomaRTNSIIISHAW(a)(15)19891915--1975Mayoretrospective study414125 years\
MAXAstrocytomaRToperative reportIIISoffietti(16)19891950--1982Italyretrospective study71717 year\
MAXAstrocytomaRTSurgeon's descriptionIIINorth(17)19901975--1984USA(Baltimore)retrospective study323269moAstrocytomaRTNSIIISHAW(18)19921960--1982Mayoretrospective study82827.1 yearsOligodendrogliomaRToperative reportIIIShibamofo(19)19931965--1989Japan (Kyoto)retrospective study676710 year\
MAXAstrocytomaRT + ChNSIIIPaolo(20)19941953--1986Italyretrospective study105105NSOligodendrogliomaRToperative reportIIIRAJAN(21)19941974--1990UKretrospective study828252moGliomaRToperative reportIIIVeelen(22)19981975--1989Netherlandsretrospective study9090120mo\
MaxAstro 72\
Oligo 14\
Mixed 4RTpatients' chartsIIIIWABUCHI(23)19991967--1993Japanretrospective study56565 yearAstrocytomaRTNSIIISmith(24)20081989--2005USA (California)retrospective study2162164.4 yearsAstrocytoma 93\
Oligodendroglioma 91\
Mixed Oligoastrocytoma 32RT + ChPatientrecordsIIIThomas B. Daniels(25)20121984--2007Japanretrospective study4242NSAstrocytoma 27\
Oligodendroglioma12\
Oligoastrocytoma7RT + ChPre- and post-operative CTIIINicolato(26)19951977--1989Italyretrospective study7674160mo\
MaxAstrocytomaRTNSIVJeremica(27)19981988--1993Japanretrospective study373774moAstrocytoma 18\
Oligodendroglioma 14\
Mixed glioma 5RToperative reportIVYEH(28)20051985--1997China (Taiwan)retrospective study9393110moAstrocytoma 46\
Oligodendroglioma 32\
Mixed 15RToperative reportIVNote: *NS* Not stated, *RT* Radiation therapy, *Ch* chemotherapy not otherwise specified

Publication bias {#Sec10}
----------------

A funnel plot was used to detect the bias in the above articles (Fig. [1](#Fig1){ref-type="fig"}). The data points were all located inside the inverted funnel, indicating a small publication bias.

Quality for the body of evidence (GRADE rating) {#Sec11}
-----------------------------------------------

The GRADE rating was performed to assess the quality of evidence in terms of the OS outcome and it was found that the quality was of a moderate level. The quality of evidence in class 2 studies was also moderate. The quality of evidence in other studies was low.

Meta-analyses for five-year survival rates {#Sec12}
------------------------------------------

Among the 20 included studies, 16 studies (1328 cases) compared the 5-year OS of patients with low-grade gliomas after GTR and STR (Fig. [2](#Fig2){ref-type="fig"}). The combined results indicated that, as compared with STR, GTR could significantly increase the 5-year survival of patients with low-grade gliomas (OR, 3.90; 95%CI,2.79\~5.45) and there was nearly no heterogeneity between studies (*P* = 0.83). Nine studies (775 cases) compared the 5-year survival between GTR and biopsy (Fig. [3](#Fig3){ref-type="fig"}). The pooled results indicated that, as compared with biopsy, GTR could significantly increase the 5-year survival of patients with low-grade gliomas (OR, 5.43; 95%CI,3.57\~8.26) and there was nearly no heterogeneity between studies (*P* = 0.23). Eleven studies (1147 cases) compared the 5-year survival of patients with low-grade gliomas between STR group and BX group. The combined results indicated that, as compared with BX, STR significantly increased the 5-year survival (OR,1.75; 95%CI,1.29\~2.37) but the heterogeneity was high (I2 = 65%, *P* = 0.001)(Fig. [4a](#Fig4){ref-type="fig"}).Based on the funnel plot, one study was excluded due to high heterogeneity. Analysis of the remaining 10 studies further proved that STR increased the 5-year survival as compared with biopsy (OR,2.59; 95%CI, 1.81\~3.71; *P* \< 0.01; Z = 5.19) (Fig. [4b](#Fig4){ref-type="fig"}).Fig. 2Forest Plot of 5-Year Overall Survival for Gross Total Resection (GTR) vs Subtotal Resection (STR)Fig. 3Forest Plot of5-Year Overall Survival for Gross Total Resection (GTR) vs Biopsy (BX)Fig. 4Forest Plot of 5-Year Overall Survival for Subtotal Resection (STR) vs Biopsy (BX)A. All related studies were included; B. All related studies except one high heterogeneous study were included

Meta-analyses for ten-year survival rates {#Sec13}
-----------------------------------------

A total of 11 studies (907 cases) compared the 10-year survival of patients with low-grade gliomas after GTR and STR. The combined results indicated that, as compared with STR, patients with GTR had the poor 10-year survival(OR,7.91; 95%CI,5.12\~12.22)and there was no apparent heterogeneity between studies (*P* = 0.33) (Fig. [5](#Fig5){ref-type="fig"}). Five studies (185 cases) compared the 10-year survival between GTR and biopsy in low-grade gliomas. The combined results indicated that, as compared with biopsy, GTR considerably increased the 10-year survival (OR,10.17; 95%CI,4.02\~25.71) and there was no heterogeneity between studies (*P* = 0.55) (Fig. [6](#Fig6){ref-type="fig"}). Six studies (408 cases) compared the 10-year survival in low-grade gliomas after STR and biopsy. The combined results indicated that, as compared with biopsy, STR considerably increased the 10-year survival(OR,2.21; 95%CI,1.16\~4.25)and there was also no heterogeneity between studies (*P* = 0.83) (Fig. [7](#Fig7){ref-type="fig"}).Fig. 5Forest Plot of 10-Year Overall Survival for Gross Total Resection (GTR) vs Subtotal Resection (STR)Fig. 6Forest Plot of 10-Year Overall Survival for Gross Total Resection (GTR) vs Biopsy (BX)Fig. 7Forest Plot of 10-Year Overall Survival for Subtotal Resection (STR) vs Biopsy (BX)

Quality for the body of evidence (GRADE rating) {#Sec14}
-----------------------------------------------

The GRADE rating was performed to assess the quality of evidence in terms of the OS outcome and it was found that the quality was of a moderate level. The quality of evidence in Level II studies was also moderate. The quality of evidence in other studies was low.

Publication bias {#Sec15}
----------------

Funnel plots were used to detect the bias in the above articles (Additional file [2](#MOESM2){ref-type="media"}: eFigure S1, Additional file [3](#MOESM3){ref-type="media"}: eFigure S2, Additional file [4](#MOESM4){ref-type="media"}: eFigure S3, Additional file [5](#MOESM5){ref-type="media"}: eFigure S4, Additional file [6](#MOESM6){ref-type="media"}: eFigure S5, Additional file [7](#MOESM7){ref-type="media"}: eFigure S6). Except studies comparing the 5-year survival of patients with low-grade gliomas between STR group and biopsy group, no publication bias was found in funnel plots, with plots visually symmetrically distributed along the vertical axis.

Discussion {#Sec16}
==========

The clinical value of surgery in low-grade gliomas is heavily disputed \[[@CR29]\]. Researchers suggest that although surgery is conducive to pathological diagnosis and remission of symptoms, some low-grade gliomas show infiltrative growth and it is difficult to achieve radical cure through a simple surgery \[[@CR30]\]. Low-grade gliomas are generally located in the brain functional areas with obscure boundaries. Surgical resection of low-grade gliomas may lead to dysfunction and impairment of patients' quality of life (QOL) \[[@CR31]\]. Some reports showed that the 5-year and 10-year survival of patients receiving GTR was comparable to those receiving STR or no surgery at all \[[@CR32]--[@CR34]\].For this reason, GTR is not the first-line therapy for low-grade gliomas. In recent years, there has been a trend of favoring GTR in the treatment of low-grade gliomas \[[@CR35], [@CR36]\].Therefore, we reviewed relevant studies published up to 2017 and performed a quantitative meta-analysis. The results showed that GTR greatly increased the 5-year and 10-year survival of patients with low-grade gliomas.

Meta-analysis can enhance the credibility of conclusions by using a larger sample size and therefore can resolve the inconsistency among different studies \[[@CR37]\]. The findings of meta-analysis are more reliable than those of a single study \[[@CR38]\]. Twenty studies focusing on the surgical outcomes of low-grade gliomas were analyzed, as the result showed in the Table [2](#Tab2){ref-type="table"}, patients with GTR had better prognosis than those with STR and biopsy, similarly, STR is superior to biopsy both in the 5-year and 10-year OS. Thus, patients with low-grade gliomas are expected to benefit from a greater extent of resection if their safety during the surgery can be ensured.Table 2Subgroup meta-analysis resultsStudy FactorsNO. of Included StudiesNO. of PatientsSurvival RateOdds Ratio M-H,Fixed (95%CI)*P*-valueI^2^statistics, *P*-valueFive-Year Overall SurvivalGTR1633680.06%3.90 \[2.79,5.45\]P\< 0.000010%, 0.83STR99254.33%GTR918472.28%5.43 \[3.57, 8.26\]P\<0.0000124%, 0.21BX57337.52%STR1046450.65%2.59 \[1.81, 3.71\]P\< 0.0000127%, 0.20BX50931.43%Five-Year Overall SurvivalGTR1122467.86%7.91\[5.12,12.22\]P\< 0.0000112%, 0.33STR68329.72%GTR58545.88%10.17\[4.02,25.71\]P\< 0.000010%, 0.55BX10012%STR622829.82%2.21\[1.16,4.25\]*P* = 0.0200%, 0.83BX12013.33%

Better outcome following GTR can be explained by the types of growth that low-grade gliomas exhibit. Firstly, the growth of low-grade gliomas can be divided into three types: confined growth, invasive growth and malignant change. According to recent studies, low-grade gliomas show continuous and slow confined growth before malignant change, resulting in an annual increase of about 4 mm in size \[[@CR30]\]. Invasive growth of low-grade gliomas is demonstrated as the invasion of adjacent white matter tracts, or even the invasion into the contralateral side via corpus callosum. In addition, low-grade gliomas may evolve into high-grade gliomas \[[@CR39]\]. It was reported that 66.4% of patients with low-grade glioma sunder went de-differentiation within 5 years after surgery, resulting in a worse prognosis \[[@CR40]\]. Therefore, early resection of tumor is very important to control infiltration and metastasis. Moreover, the reduction in the tumor load is also conducive to improve effectiveness of subsequent radiochemotherapy. Secondly, from the pathological aspect, histopathology remains the gold standard for the malignancy classification of gliomas. The accuracy of histopathological diagnosis depends on whether a submitted sample is representative \[[@CR41]\]. Gliomas are usually associated with heterogeneity in terms of the varying types of cells and different degrees of malignancy in the tumor. That is why the representativeness of the submitted sample is crucial for pathological diagnosis \[[@CR42]\]. In one study, a pathological diagnosis based on stereotactic biopsy of astrocytoma was compared with the diagnosis obtained from a surgically resected sample. It was found that sterotactic biopsy underestimated the grades of tumors in 10%--25% of the cases \[[@CR43]\]. Therefore, an extensive resection of low-grade gliomas and the submission of all resected specimens for pathological examination can reduce diagnostic errors.

However, some studies might have biases due to limited technical skills and defects in their experimental designs \[[@CR44]\]. For example, many researches concerning surgical treatment for low-grade gliomas were retrospective studies. In other studies, the extent of resection was determined based on neurosurgeons' experience or CT scan, which might lead to inconsistent conclusions. Recently, National Cancer Institute (NCI) presented a statistics report on the survival of 2009 patients with low-grade gliomas between 1973 and 2001 \[[@CR35]\]. The results showed that surgery prolonged the survival of these patients.

There were other limitations in our study. On the one hand, our meta-analysis included only one prospective and randomized controlled clinical trial while most of the included articles were retrospective studies. There were only four Level II studies included in our analysis while many of the remaining studies were of Level III. However, all results from Level II studies were consistent with our result which favored GTR over STR and biopsy. On the other hand, as mentioned above, low-grade gliomas have a much lower incidence than that of high-grade gliomas, leading to a smaller number of eligible trials in the meta-analysis, so large-scale randomized clinical trials for low-grade gliomas are urgently needed. Additionally, there were some covariates between studies, such as patients' age, auxiliary treatment methods, tumor size and complications, which could bring some bias to our study.

Conclusion {#Sec17}
==========

Our meta-analysis included only one prospective and randomized controlled clinical trial while most of the included articles were retrospective studies. All evidences were consistent (four class 2 studies) in that they favored GTR over STR and biopsy. There were four class2 studies while many of the remaining studies were of class3. We believe that, as compared with STR and biopsy, GTR could significantly increase the 5-year and 10-year survival of patients with low-grade gliomas. If feasible, GTR is recommended for those patients newly diagnosed as low-grade gliomas. Based on the existing evidences, we believe that more retrospective cohort studies may not provide more useful data. Instead, for low-grade gliomas, high-quality prospective clinical trials are needed to analyze the prognostic factors such as the extent of resection, auxiliary treatment, tumor size, tumor location and complications.
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:   Biopsy

Ch

:   Chemotherapy not otherwise specified

CI

:   Confidence interval

GTR

:   Gross total resection

NCI

:   National Cancer Institute
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:   Not stated

OR

:   Odds ratio

OS

:   Overall survival

PFS

:   Progression-free survival

QOL

:   Quality of life

RCT

:   Randomized and controlled trial

RT

:   Radiation therapy
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:   Subtotal resection
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